Cazzola M. Myelodysplastic Syndromes. N Engl J Med. 2020;383:1358–74.

Article  CAS  PubMed  Google Scholar 

Sébert M. Next-generation therapy for lower-risk MDS. Hematology Am Soc Hematol Educ Program. 2023;2023:59–64.

Article  PubMed  Google Scholar 

Arber DA, Orazi A, Hasserjian RP, Borowitz MJ, Calvo KR, Kvasnicka H-M, et al. International Consensus Classification of Myeloid Neoplasms and Acute Leukemias: integrating morphologic, clinical, and genomic data. Blood. 2022;140:1200–28.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Loghavi S, Kanagal-Shamanna R, Khoury JD, Medeiros LJ, Naresh KN, Nejati R, et al. Fifth Edition of the World Health Classification of Tumors of the Hematopoietic and Lymphoid Tissue: Myeloid Neoplasms. Mod Pathol. 2024;37: 100397.

Article  PubMed  Google Scholar 

Jiang M, Chen M, Liu Q, Jin Z, Yang X, Zhang W. SF3B1 mutations in myelodysplastic syndromes: A potential therapeutic target for modulating the entire disease process. Front Oncol. 2023;13:1116438.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Greenberg P, Cox C, LeBeau MM, Fenaux P, Morel P, Sanz G, et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079–88.

Article  CAS  PubMed  Google Scholar 

Greenberg PL, Tuechler H, Schanz J, Sanz G, Garcia-Manero G, Solé F, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012;120:2454–65.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bernard E, Tuechler H, Greenberg PL, Hasserjian RP, Arango Ossa JE, Nannya Y, et al. Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. NEJM Evid. 2022;1:EVIDoa2200008.

Article  PubMed  Google Scholar 

Pfeilstöcker M, Tuechler H, Sanz G, Schanz J, Garcia-Manero G, Solé F, et al. Time-dependent changes in mortality and transformation risk in MDS. Blood. 2016;128:902–10. https://doi.org/10.1182/blood-2016-02-700054. Helped to establish an IPSS-R cut-off to defined lower-risk MDS in comparison to higher-risk MDS.

Brunner AM, Leitch HA, van de Loosdrecht AA, Bonadies N. Management of patients with lower-risk myelodysplastic syndromes. Blood Cancer J. 2022;12:166.

Article  PubMed  PubMed Central  Google Scholar 

Stojkov K, Silzle T, Stussi G, Schwappach D, Bernhard J, Bowen D, et al. Guideline-based indicators for adult patients with myelodysplastic syndromes. Blood Adv. 2020;4:4029–44.

Article  PubMed  PubMed Central  Google Scholar 

Sauta E, Robin M, Bersanelli M, Travaglino E, Meggendorfer M, Zhao L-P, et al. Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes. J Clin Oncol. 2023;41:2827–42.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bănescu C, Tripon F, Muntean C. The Genetic Landscape of Myelodysplastic Neoplasm Progression to Acute Myeloid Leukemia. Int J Mol Sci [Internet]. 2023;24. Available from: https://doi.org/10.3390/ijms24065734.

Buckstein R, Chodirker L, Mozessohn L, Yee KWL, Geddes M, Zhu N, et al. A natural history of lower-risk myelodysplastic syndromes with ring sideroblasts: an analysis of the MDS-CAN registry. Leuk Lymphoma. 2022;63:3165–74.

Article  PubMed  Google Scholar 

Jain AG, Ball S, Aguirre L, Al Ali N, Kaldas D, Tinsley-Vance S, et al. Patterns of lower risk myelodysplastic syndrome progression: factors predicting progression to high-risk myelodysplastic syndrome and acute myeloid leukemia. Haematologica. 2024. https://doi.org/10.3324/haematol.2023.283661. A comprehensive analysis of patients with lower-risk MDS to describe rates of disease progression over an extended period of time.

Mądry K, Lis K, Fenaux P, Bowen D, Symeonidis A, Mittelman M, et al. Cause of death and excess mortality in patients with lower-risk myelodysplastic syndromes (MDS): A report from the European MDS registry. Br J Haematol. 2023;200:451–61.

Article  PubMed  Google Scholar 

Randall MP, DeZern AE. The Management of Low-Risk Myelodysplastic Syndromes-Current Standards and Recent Advances. Cancer J. 2023;29:152–9.

Article  CAS  PubMed  Google Scholar 

Santini V. Treatment of low-risk myelodysplastic syndromes. Hematology Am Soc Hematol Educ Program. 2016;2016:462–9.

Article  PubMed  PubMed Central  Google Scholar 

Komrokji RS, Sengupta N, Supina D, Navada S, Potluri R, Tyagi R, et al. Durable Transfusion Independence in Lower-Risk Myelodysplastic Syndrome (LR-MDS) Is Associated with Better Survival: A Population Level Analysis Based on a Large US Health Insurance Claims Database. Blood. 2023;142:2440.

Article  Google Scholar 

de Swart L, Crouch S, Hoeks M, Smith A, Langemeijer S, Fenaux P, et al. Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica. 2020;105:632–9.

Article  PubMed  PubMed Central  Google Scholar 

Kim N, Pavletic S, Norsworthy KJ. Meaningful response criteria for myelodysplastic syndromes. Br J Haematol. 2022;196:1137–48.

Article  PubMed  Google Scholar 

Platzbecker U, Fenaux P, Adès L, Giagounidis A, Santini V, van de Loosdrecht AA, et al. Proposals for revised IWG 2018 hematological response criteria in patients with MDS included in clinical trials. Blood. 2019;133:1020–30.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Balducci L. Transfusion independence in patients with myelodysplastic syndromes: impact on outcomes and quality of life. Cancer. 2006;106:2087–94.

Article  PubMed  Google Scholar 

Stauder R, Yu G, Koinig KA, Bagguley T, Fenaux P, Symeonidis A, et al. Health-related quality of life in lower-risk MDS patients compared with age- and sex-matched reference populations: a European LeukemiaNet study. Leukemia. 2018;32:1380–92.

Article  PubMed  PubMed Central  Google Scholar 

Szende A, Schaefer C, Goss TF, Heptinstall K, Knight R, Lübbert M, et al. Valuation of transfusion-free living in MDS: results of health utility interviews with patients. Health Qual Life Outcomes. 2009;7:81.

Article  PubMed  PubMed Central  Google Scholar 

Vijenthira A, Starkman R, Lin Y, Stanworth SJ, Bowen D, Harrison L, et al. Multi-national survey of transfusion experiences and preferences of patients with myelodysplastic syndrome. Transfusion. 2022;62:1355–64.

Article  PubMed  Google Scholar 

Buckstein R, Callum J, Prica A, Bowen D, Wells RA, Leber B, et al. Red cell transfusion thresholds in outpatients with myelodysplastic syndromes: Combined results from two randomized controlled feasibility studies. Am J Hematol. 2024;99:473–6.

Article  PubMed  Google Scholar 

Zeidner JF, Mazerolle F, Norton J, Regnault A, Kristo F, Romero H, et al. Time without transfusion reliance: a novel patient-centric metric for new therapies in myelodysplastic syndromes. Haematologica. 2023;108:1196–9. https://doi.org/10.3324/haematol.2022.281856. A novel assessment of transfusion independence in patients with lower-risk MDS that may better capture the benefit of achieving this endpoint.

Hellström-Lindberg ES, Kröger N. Clinical decision-making and treatment of myelodysplastic syndromes. Blood. 2023. p. 2268–81. https://doi.org/10.1182/blood.2023020079.

Shenoy N, Vallumsetla N, Rachmilewitz E, Verma A, Ginzburg Y. Impact of iron overload and potential benefit from iron chelation in low-risk myelodysplastic syndrome. Blood. 2014;124:873–81.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hoeks M, Yu G, Langemeijer S, Crouch S, de Swart L, Fenaux P, et al. Impact of treatment with iron chelation therapy in patients with lower-risk myelodysplastic syndromes participating in the European MDS registry. Haematologica. 2020;105:640–51.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Oliva EN, Ronco F, Marino A, Alati C, Praticò G, Nobile F. Iron chelation therapy associated with improvement of hematopoiesis in transfusion-dependent patients. Transfusion. 2010;50:1568–70.

Article  PubMed  Google Scholar 

Badawi MA, Vickars LM, Chase JM, Leitch HA. Red blood cell transfusion independence following the initiation of iron chelation therapy in myelodysplastic syndrome. Adv Hematol. 2010;2010: 164045.

Article  PubMed  PubMed Central  Google Scholar 

Angelucci E, Li J, Greenberg P, Wu D, Hou M, Montano Figueroa EH, et al. Iron Chelation in Transfusion-Dependent Patients With Low- to Intermediate-1-Risk Myelodysplastic Syndromes: A Randomized Trial. Ann Intern Med. 2020;172:513–22.

Article  PubMed  Google Scholar 

Gabrilove J, Paquette R, Lyons RM, Mushtaq C, Sekeres MA, Tomita D, et al. Phase 2, single-arm trial to evaluate the effectiveness of darbepoetin alfa for correcting anaemia in patients with myelodysplastic syndromes. Br J Haematol. 2008;142:379–93.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Fenaux P, Santini V, Spiriti MAA, Giagounidis A, Schlag R, Radinoff A, et al. A phase 3 randomized, placebo-controlled study assessing the efficacy and safety of epoetin-α in anemic patients with low-risk MDS. Leukemia. 2018;32:2648–58.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Krönke J, Fink EC, Hollenbach PW, MacBeth KJ, Hurst SN, Udeshi ND, et al. Lenalidomide induces ubiquitination and degradation of CK1α in del(5q) MDS. Nature. 2015;523:183–8.

Article  PubMed  PubMed Central  Google Scholar 

List A, Kurtin S, Roe DJ, Buresh A, Mahadevan D, Fuchs D, et al. Efficacy of lenalidomide in myelodysplastic syndromes. N Engl J Med. 2005;352:549–57. https://doi.org/10.1056/NEJMoa041668. Seminal trial demonstrating the high efficacy of lenalidomide in del5q syndrome.

List A, Dewald G, Bennett J, Giagounidis A, Raza A, Feldman E, et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med. 2006;355:1456–65.

Article  CAS  PubMed  Google Scholar 

Fenaux P, Giagounidis A, Selleslag D, Beyne-Rauzy O, Mufti G, Mittelman M, et al. A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood. 2011;118:3765–76.

Article  CAS